OMass’s molecule is vying to change into a substitute for a Neurocrine Biosciences drug that’s at the moment the one FDA-approved remedy for congenital adrenal hyperplasia. However Vertex Prescription drugs may additionally compete with a drug candidate from a latest acquisition.
The submit Startup OMass Secures $310M to Advance Drug for Uncommon Endocrine Dysfunction appeared first on MedCity Information.
Discover the latest in health and fitness with Your Health 247. Get expert advice, workout routines, healthy recipes, and mental wellness tips to lead a healthier, happier life. Stay informed and empowered with us!
